Technical know-how for a solid economic dossier

Health economics

Facing increasing pressure to contain the growth of health care expenditures, payers must make hard choices between multiple existing and new interventions. To secure reimbursement or support price negotiations, it is essential to demonstrate that your product represents efficient use of available funding.

Our health economics experts can help you throughout the product lifecycle to perform:

  • Cost-effectiveness and budget impact modeling
  • Cost-effectiveness analysis alongside clinical trials
  • Go/no-go models to inform internal decision-making
  • Cost of illness studies
  • Dossier preparation for Health Technology Assessment (HTA) submissions
  • Preference elicitation studies (e.g. discrete choice experiments, time trade-off or standard gamble)

Contact us to find out how our expertise in health economics can help your product demonstrate real value for money.

Recent projects

Parkinson’s disease economic model for a reimbursement dossier in Norway and Portugal

A health economic model was developed to evaluate the cost-effectiveness of a novel medication aimed at disease modification, from the time of diagnosis of Parkinson’s disease. The aim of the analysis was to evaluate the long-term effect of the first treatment that was able to demonstrate a disease-modifying effect in Parkinson’s disease. The health economic model was developed as part of a preparation of a reimbursement submission in two European countries, Norway and Portugal. Project work included collection and synthesis of data used to populate the model, development and programming of the model and a detailed report of the analysis. The results of this research indicated that this novel medication was a cost-effective strategy when compared with treatment as usual in both countries.

Critical literature review of cost-effectiveness and budget-impact analyses for a vaccine

Economic evaluations in rotavirus vaccination are numerous, and several literature reviews already existed. However, none provided a thorough critical appraisal of the models and input data. We conducted a comprehensive and organized review or published evaluations for the two commercialised vaccines, and critically appraised those evaluations. All input data, assumptions, and results were extracted in a systematic manner. More than 100 economic evaluations were reviewed. Based on this work, we were able to provide insight into differences between results of different published evaluations, and our report provided recommendations for future economic evaluations to be performed by our client.
Aballéa S, Millier A, Quilici S, Caroll S, Petrou S, Toumi M. A critical literature review of health economic evaluations of rotavirus vaccination. Hum VaccinImmunother. 2013 Jun 1;9(6):1272-1288.


Modelling the consequences of heavy drinking days and total alcohol consumption in terms of alcohol-attributable diseases and injuries

Our client developed a new treatment for patients with alcohol-dependence. This treatment was shown to be associated with a significant reduction in the number of heavy-drinking days (HDD) per month and in average daily alcohol consumption among alcohol-dependent patients. However, clinical trials were not large enough to demonstrate the impact of the product in terms of alcohol-related complications. We developed a microsimulation model to predict the reduction in risk of alcohol-related diseases or injuries associated with a reduction in alcohol consumption. The model simulated alcohol consumption day-by-day for a large cohort of patients and predicted the risks of diseases and injuries for each simulated patient, according to alcohol consumption. It used equations linking alcohol consumption to risks of diseases and injuries, derived from numerous epidemiological diseases. Microsimulation was required because of the complexity of the relationships between alcohol consumptions and risks of alcohol-related complications. This model was used as part of the regulatory dossier for the product and contributed to the approval of the product by EMA.